HC Wainwright & Co. maintains Greenwich LifeSciences at Buy, raises price target to $70 from $69
HC Wainwright & Co. kept its Buy rating on Greenwich LifeSciences and increased its price target to $70 from $69, suggesting a 274.3% upside from the Nov 17 close of $18.70.

